Impact of RSV test positivity, patient characteristics, and treatment characteristics on the cost of hospitalization for acute bronchiolitis in a French university medical center (2010–2015)

Frontiers in Pediatrics

Pediatrics

Marine Van Berleere¹  Benoit Dervaux¹  Xavier Lenne²  Marine Wyckaert³  François Dubos⁴ 

[1] CHU Lille, Direction de la Recherche et de l’Innovation, Lille, France;CHU Lille, Département d’Information Médicale, Lille, France;CHU Lille, Urgences pédiatriques & maladies infectieuses, Lille, France;CHU Lille, Urgences pédiatriques & maladies infectieuses, Lille, France;Univ Lille, ULR 2694 - Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France;

关键词: bronchiolitis;    cost analysis;    hospitalization costs;    RSV infections;    viral respiratory infection;   

DOI  :  10.3389/fped.2023.1126229

 received in 2022-12-17, accepted in 2023-06-27,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundIn young children, respiratory syncytial virus (RSV)-related bronchiolitis is typically more severe than other respiratory tract infections, with a greater need for oxygen therapy and respiratory support. Few studies have compared the cost of hospitalization with regard to virological status. The objective of this study was to compare the costs of hospitalization for RSV-positive vs. RSV-negative bronchiolitis in a French university medical center between 2010 and 2015.MethodsThe cost models were compared using conventional goodness-of-fit criteria. Covariates included the characteristics of the patients, pre-existing respiratory and non-respiratory comorbidities, superinfections, medical care provided, and the length of stay.ResultsRSV was detected in 679 (58.3%) of the 1,164 hospital stays by children under 2 years with virological data. Oxygen therapy and respiratory support were twice as frequent for the RSV-positive cases. The median hospitalization cost was estimated at €3,248.4 (interquartile range: €2,572.1). The cost distribution was positively skewed with a variation coefficient (CV = standard deviation/mean) greater than one (mean = €4,212.9, standard deviation = €5,047, CV = 1.2). In univariate analyses, there was no significant cost difference between the RSV-positive and RSV-negative cases. In the best multivariate model, the significant positive effect of RSV positivity on cost waned after the introduction of medical care variables and the length of stay. The results were sensitive to the specification of the model.ConclusionsIt was impossible to firmly conclude that hospitalization costs were higher for the RSV-positive cases.

【 授权许可】

Unknown   
© 2023 Dervaux, Van Berleere, Lenne, Wyckaert and Dubos.